Inaugural list of price controls on U.S. medicines means hard choices for investors

by John Stanford

The Centers for Medicare & Medicaid Services recently announced the first 10 drugs that will be subject to Medicare’s new price controls. More drugs will follow each year.

Industry is grappling with the effects this change will have on new drug development -- and it’s clear that law...